Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President of Investor Relations, Corporate Communications Conference Call Participants Chase Knickerbocker - Craig-Hallam Leland Gershell - Oppenheimer. Oren Livnat - HC Wainwright Nik Gasic - Leerink Partners David Amsellem - Piper Sandler Operator Hello and welcome to the Xeris Biopharma Third Quarter 2024 Financial Results Conference Call.

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago.

Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2024. “We are proud to report our record-breaking quarter with total revenue of our $54 million led by strong demand of Recorlev® and Gvoke®. Our product revenue growth of 2.

Xeris Biopharma Reports Third Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Friday, November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss t.

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative injectable drug formulations. Gvoke and Recorlev drive Xeris' rapid growth, with Gvoke holding 34% of the retail glucagon market and Recorlev expanding its patient base by 124%. Xeris' strategic partnerships and promising pipeline, particularly XP-8121 for hypothyroidism, offer strong potential for value creation and long-term growth.

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Generac Holdings

KinderCare Learning Cos Inc

Royal Philips

The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 4th - 10th, aiming to inspire discussion and provide investment ideas. WW International's pivot to GLP-1 medications raises concerns for Dilantha De Silva about growth and customer churn, leading to a bearish stance despite recent stock gains. Fresenius Medical Care shows Wolf Report potential for growth despite recent earnings declines, with a BBB rating and attractive yield as rate cuts loom.

Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +

Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke and Recorlev, despite not yet reporting a positive EPS. Risks include intense competition and potential need for additional funding, but projected revenue growth suggests significant upside potential.

Xeris Biopharma: Time For A Reassessment

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 364,000 shares of its common stock to 42 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Eq.

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Lyell Immunopharma

Precigen

Are you interested in investing in penny stocks?

3 Penny Stocks to Buy With $500

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events: 2024 Wells Fargo Healthcare Conference, Boston, MA Meetings only on September 4, 2024 H.C. Wainwright 26th Annual Global Investor Conference, New York, NY Meetings an.

Xeris to Participate in Upcoming Investor Conferences

Start Time: 08:30 January 1, 0000 9:03 AM ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants John Shannon - CEO Steven Pieper - CFO Allison Wey - SVP, IR and Corporate Communications Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Rohan Mathur - Oppenheimer Operator Hello, everyone, and welcome to today's Xeris Biopharma Second Quarter 2024 Financial Results Call. My name is Drew, and I'll be your operator today.

Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript

Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago.

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30, 2024 and recent corporate events. “I am very pleased to report that we posted an outstanding quarter of $48 million in total revenue, which included record product revenue of ove.

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Thursday, August 8, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss.

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?

Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his roles after more than seven years with the company.

Xeris Biopharma unveils CEO succession plan, John Shannon to lead company

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 2024, under which Paul R. Edick will be retiring from his day-to-day operational and Chairman role at Xeris after more than seven years with the Company. Pursuant to the Company's succession plan, the Boa.

Xeris Biopharma Announces CEO Succession Plan

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing's syndrome at ENDO 2024 in Boston, June 1-4, 2024. “The results of this analysis suggest that pati.

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company's XeriSol™ formulation technology to enable a novel once-weekly SC injec.

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time. A live webcast of the event will be available on the 'Events & Presentations.

Xeris to Participate in the Jefferies Global Healthcare Conference

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steven Pieper - CFO Conference Call Participants Oren Livnat - H.C. Wainwright & Co. Roanna Ruiz - Leerink Partners Rohan Mathur - Oppenheimer Kelly Close - Analyst Operator Hello, everyone, and welcome to the Xeris Biopharma First Quarter 2024 Financial Results Conference Call and Webcast.

Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript

Xeris Biopharma Holdings (NASDAQ:XERS) revealed a robust growth trajectory in its first quarter, with total product revenue surging 25% compared to the previous year's quarter. Paul Edick, CEO of Xeris, cited significant momentum in Recorlev sales, the steadfastness of Keveyis in the market, and the expanding market share of Gvoke as key drivers of the firm's performance over the quarter.

Xeris Biopharma sees 1Q revenue jump on strength of product sales

Xeris Biopharma (XERS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.

News for Xeris Biopharma Holdings Stock (XERS)